(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Cancer Biomarkers market has also been witnessing the trend of the emergence of personalized medicines. However, the poor regulatory and reimbursement systems could pose a challenge to the growth of this market.
The key vendors dominating this market space are Abbott Laboratories, Affymetrix, Inc., Agilent Technologies Inc., Gen-Probe Inc., Hologic, Inc., and Roche Diagnostics Corp.
The other vendors mentioned in the report are Agendia BV, Ambrilia Biopharma, Astellas Pharma US Inc., Morphotek, Inc., Gen-Probe, Inc., Veridex LLC, Morphotek, Inc., Immunomedics, Inc., Clarient, Inc.
Commenting on the report, an analyst from TechNavio's Healthcare team said: ''Over the years, personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. Personalized medicines are increasingly being used in targeted cancer therapies. As personalized medicines gain more importance and popularity, the demand for biomarkers is expected to increase. In the coming years, as personalized medicines become more popular, conventional approaches will automatically become obsolete.''
Further, the report reveals that one of the key challenges is the existence of poor regulatory and reimbursement systems.
For more information visit http://www.researchandmarkets.com/research/mrb9sm/global_cancer
Research and MarketsLaura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology
SOURCE Research and Markets
No comments:
Post a Comment